This trial is evaluating whether ABX464 will improve 1 primary outcome and 13 secondary outcomes in patients with Colitis, Ulcerative. Measurement will happen over the course of From baseline to week 48.
This trial requires 217 total participants across 1 different treatment group
This trial involves a single treatment. ABX464 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"This review suggests that smoking may be a risk factor for IBD. While there is little evidence for other potential causes, the fact that IBD is associated with environmental factors should not be forgotten." - Anonymous Online Contributor
"Crohn disease is commonly treated through a variety of treatments: NSAIDS, anti-inflammatory medications; steroids; and alternative treatments such as massage and herbal remedies, and electroacupuncture." - Anonymous Online Contributor
"In many IBD patients the colon is the site of colitis and chronic inflammation. In the ulcerative colitis patients, inflammation of the colon causes diarrhea (either with or without blood in stools) and rectal bleeding.\n\nThis is the first issue of the newsletter to be published in English.\n\n- New England Journal of Medicine"" - Anonymous Online Contributor
"Colitis and ulcerative can be cured with the use of drugs or with a low-calorie diet. However, the effects remain for a limited number of patients, and treatment must be planned on the basis of individual risk factors, severity of disease, and willingness of the patient for adherence to treatment plans of extended duration." - Anonymous Online Contributor
"Colitis can be mistaken for other gastrointestinal conditions which are characterized by watery diarrhea, abdominal pain, dehydration, and weight loss. Colitis can present with dysplasia, which manifests as a tan, yellow, or red discoloration of the stool that can be mistaken for blood. A complete workup of stool and blood is needed for diagnosis." - Anonymous Online Contributor
"Around 2.6 million people are affected by UC each year in the United States, which comprises 4%, more than colorectal cancer. Because of the high lifetime prevalence of UC, a substantial number of affected individuals will be aged by age 20." - Anonymous Online Contributor
"Abx464 is a unique, once-in-a-lifetime therapeutic for severe active ulcerative colitis by combining it with standard colonic hygiene and anti-inflammatories. In addition such a formulation can improve the patient’s quality of life and minimize further damage in a most humane and cost-effective way." - Anonymous Online Contributor
"Abx464 is an orally available first-in-class, bi-functional, polypharmaceutically-modified, synthetic peptide therapeutically targeting Th1-driven inflammatory cytokine response. This novel therapeutic approach shows promising activity in a relevant model of colitis. Further proof of concept and safety will be necessary prior to starting clinical trials." - Anonymous Online Contributor
"The efficacy of a novel small molecule compound, AUBX464, in treating colitis in mice has been demonstrated for the first time, and a new target for the treatment of inflammatory diseases, the sphingosine-1-phosphate receptor 5, was identified." - Anonymous Online Contributor
"In our opinion, patients who have not responded to treatment with standard dose drugs can be benefited from a well-thought out scheme of combined and intensive treatment." - Anonymous Online Contributor
"The latest news on colitis, ulcerative may help you understand about the disease. Most of colitis, ulcerative happens due to viruses. People's diet are closely correlated with colitis, ulcerative since people tend to eat high-fat, high-sugar, trans fat, low-fiber and high salt foods. These foods have the potential to cause colitis in some people. So, people will need to be careful to keep diet changes. On other hand, colitis, ulcerative can be treated. Taking medications can help to manage the disease, and the patient will feel better after the medication is taken." - Anonymous Online Contributor
"In both placebo-controlled and open-label trials the clinical superiority of BCL-354 over a placebo formulation for the treatment of active ulcerative colitis in terms of the percentage of patients who met the primary endpoints and the degree of improvement in stool indices was confirmed." - Anonymous Online Contributor